Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SIBN 
Si-Bone Inc (SIBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SIBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25
1 Year Target Price $25
| 5 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.95% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 660.06M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 9 | Beta 0.92 | 52 Weeks Range 11.70 - 20.05 | Updated Date 08/15/2025 |
52 Weeks Range 11.70 - 20.05 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -0.1833 | Actual -0.14 |
Profitability
Profit Margin -12.83% | Operating Margin (TTM) -14.4% |
Management Effectiveness
Return on Assets (TTM) -7.59% | Return on Equity (TTM) -14.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 568702695 | Price to Sales(TTM) 3.56 |
Enterprise Value 568702695 | Price to Sales(TTM) 3.56 | ||
Enterprise Value to Revenue 3.07 | Enterprise Value to EBITDA -14.15 | Shares Outstanding 43140900 | Shares Floating 38417435 |
Shares Outstanding 43140900 | Shares Floating 38417435 | ||
Percent Insiders 3.03 | Percent Institutions 93.05 |
Upturn AI SWOT
Si-Bone Inc
Company Overview
History and Background
SI-BONE, Inc. was founded in 2008 and is headquartered in Santa Clara, California. It is a medical device company focused on developing and commercializing products for the treatment of sacroiliac (SI) joint dysfunction. The company's primary focus has been on minimally invasive surgical solutions for SI joint fusion.
Core Business Areas
- Sacroiliac Joint Fusion: SI-BONE's core business revolves around providing surgical solutions for SI joint dysfunction. Their primary product, the iFuse Implant System, is used to stabilize and fuse the SI joint. They focus on developing advanced tools and techniques for minimally invasive procedures.
Leadership and Structure
SI-BONE's leadership team typically consists of a CEO, CFO, and other key executives overseeing various departments such as R&D, marketing, and sales. The organizational structure likely includes functional departments responsible for product development, manufacturing, sales, and marketing. Current CEO is Laura A. Francis.
Top Products and Market Share
Key Offerings
- iFuse Implant System: The iFuse Implant System is SI-BONE's flagship product, designed for minimally invasive SI joint fusion. It consists of titanium implants that are inserted across the SI joint to stabilize and fuse it. Market share data specific to iFuse is variable depending on the source, but it is considered a leader in the SI joint fusion market. Competitors include Medtronic (Invicept), RTI Surgical (SImmetry Sacroiliac Joint Fusion System), and Globus Medical. Revenue tied to iFuse is approximately 98% of their total revenue.
Market Dynamics
Industry Overview
The medical device industry focusing on SI joint dysfunction is growing due to increased awareness and diagnosis rates. The market is driven by the demand for minimally invasive surgical solutions to alleviate chronic lower back pain related to the SI joint.
Positioning
SI-BONE is positioned as a leader in the SI joint fusion market, particularly with its iFuse Implant System. Its competitive advantages include clinical evidence supporting the effectiveness of iFuse and a focus on minimally invasive techniques.
Total Addressable Market (TAM)
The estimated total addressable market (TAM) for SI joint fusion procedures is estimated to be in the hundreds of millions of dollars annually in the US alone. SI-BONE is positioned to capture a significant portion of this market through continued product innovation and market penetration. It is estimated to be $2 Billion in the US.
Upturn SWOT Analysis
Strengths
- Strong clinical data supporting iFuse
- Focus on minimally invasive techniques
- Established market presence in SI joint fusion
- Proprietary iFuse technology
Weaknesses
- Reliance on a single product (iFuse)
- Limited diversification
- Reimbursement challenges from insurance providers can impact adoption
- Profitability challenges
Opportunities
- Expanding market awareness and diagnosis of SI joint dysfunction
- Developing new products and applications for SI joint fusion
- Increasing market penetration through partnerships and acquisitions
- Geographic expansion into new markets
Threats
- Competition from other medical device companies
- Changes in reimbursement policies
- Technological advancements leading to alternative treatments
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- GMED
- NXTC
Competitive Landscape
SI-BONE faces competition from larger medical device companies, such as Medtronic and Globus Medical, that may have greater resources and broader product portfolios. SI-BONE's advantages include its focused expertise in SI joint fusion and strong clinical evidence supporting iFuse. Its disadvantage is profitability and relying on a single product.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by increased adoption of iFuse. However, it is important to note the company's challenges in achieving profitability.
Future Projections: Future growth projections depend on factors such as market penetration, product innovation, and reimbursement rates. Analyst estimates vary, so users should perform their own due diligence.
Recent Initiatives: Recent initiatives may include expanding sales and marketing efforts, developing new iFuse applications, and pursuing strategic partnerships.
Summary
SI-BONE is a leader in the SI joint fusion market with its iFuse product, supported by strong clinical data. However, the company is challenged by its reliance on a single product, profitability concerns, and the presence of larger competitors. Successful expansion into new markets and continued product innovation will be crucial for future growth. Potential reimbursement changes from insurance providers need to be watched carefully. Overall SIBN has a Strong product but a weak balance sheet to support future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Company Investor Relations
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Si-Bone Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2018-10-17 | CEO & Director Ms. Laura A. Francis MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 349 | Website https://si-bone.com |
Full time employees 349 | Website https://si-bone.com | ||
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.